HC Wainwright Has Positive Estimate for DBVT FY2024 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for DBV Technologies in a report issued on Wednesday, October 23rd. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.41) for the year, up from their previous forecast of ($1.43). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

Several other equities research analysts have also weighed in on DBVT. StockNews.com began coverage on DBV Technologies in a research note on Monday. They set a “hold” rating for the company. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Stock Performance

Shares of NASDAQ:DBVT opened at $0.84 on Friday. The stock has a market capitalization of $80.81 million, a price-to-earnings ratio of -1.00 and a beta of 0.67. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.28. The company has a 50 day moving average price of $0.78 and a 200 day moving average price of $0.96.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. During the same quarter last year, the business posted ($0.26) EPS.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies makes up 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.